Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313

K. Ramanathan, Ramesh; McDonough, Shannon; A. Philip, Philip; R. Hingorani, Sunil; Lacy, Jill; Kortmansky, Jeremy; Thumar, Jaykumar; Gabriela Chiorean, E.; F. Shields, Anthony; Behl, Deepti; Mehan, Paul; Gaur, Rakesh; Elisabeth Seery, Tara; A. Guthrie, Katherine; S. Höchster, Howard

doi:10.1200/jco.18.01295

Public

Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313

Published in Journal of Clinical Oncology • Feb 28, 2019

Authors:

Ramesh K. Ramanathan

Shannon McDonough

Philip A. Philip

Abstract

PURPOSE: Pegylated recombinant human hyaluronidase (PEGPH20) degrades hyaluronan (HA) and, in combination with chemotherapy, prolongs survival in preclinical models. The activity of PEGPH20 with modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) was evaluated in patients wi...

Subject

Medicine

FOLFIRINOX

Gemcitabine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!